Oncolytic herpes simplex virus vectors for cancer virotherapy

Related Experiment Video

Updated: Sep 27, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Susan Varghese1, Samuel D Rabkin

  • 1Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA.

Cancer Gene Therapy
|January 11, 2003
PubMed

Insights

Oncolytic herpes simplex virus type 1 (HSV-1) vectors show promise as a cancer therapy. These modified viruses are safe and effective against various solid tumors, especially when combined with traditional treatments.

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy
  • Cancer research

Background:

  • Herpes simplex virus type 1 (HSV-1) vectors are being developed for cancer treatment.
  • Modified HSV-1 vectors aim to reduce pathogenicity while maintaining efficacy.
  • Clinical trials are evaluating the safety and effectiveness of these oncolytic viruses.

Purpose of the Study:

  • To assess the safety and efficacy of oncolytic HSV-1 vectors in preclinical cancer models.
  • To investigate the potential of HSV-1 vectors as a standalone and combination cancer therapy.
  • To explore the use of engineered HSV-1 vectors expressing therapeutic genes.

Main Methods:

  • Development of replication-competent HSV-1 vectors with specific gene mutations.
  • Testing of viral safety and efficacy in various mouse cancer models (glioma, melanoma, breast, etc.).
  • Evaluation of HSV-1 vectors in combination with radiotherapy and chemotherapy.

Main Results:

  • HSV-1 vectors demonstrated safety, even after administration into the brain.
  • Significant efficacy was observed against a wide range of solid tumors in mice.
  • Combination therapy with radiotherapy and chemotherapy enhanced anti-tumor activity.
  • Phase I clinical trials reported no adverse events attributed to the virus.

Conclusions:

  • Oncolytic HSV-1 vectors represent a safe and effective therapeutic strategy for diverse cancers.
  • Combining HSV-1 vectors with conventional treatments offers a promising clinical approach.
  • Further advancements in delivery and specificity will enhance the clinical translation of oncolytic HSV-1 therapies.

More Related Videos

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...